+ Watch PCYC
on My Watchlist
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
They may very well get something to market (eventually...haven't done enough diligence on the pipeline), but being valued at 3.5 billion when they don't even have any Phase III trials started yet is absurd.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions